Taking 300 mg of Ashwagandha or 3 mg of melatonin daily for two months helps adults with mild sleep problems fall asleep faster and sleep longer than taking a placebo, but the combination of both supplements works even better.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether standardized Ashwagandha (300–600 mg/day) and melatonin (1–5 mg/day) consistently improve sleep onset latency and total sleep time across diverse populations with mild-to-moderate sleep disturbance, accounting for formulation and duration differences.
A systematic review and meta-analysis of at least 12 RCTs comparing Ashwagandha (300 mg/day) or melatonin (3 mg/day) versus placebo in adults aged 18–60 with DSM-5-defined sleep disturbance, using actigraphy for SOL and TST as primary outcomes, with follow-up ≥8 weeks and standardized effect size reporting.
That 300 mg Ashwagandha and 3 mg melatonin each causally improve sleep onset latency and total sleep time in a broader population, including those with comorbid anxiety or shift work.
A multicenter, double-blind, placebo-controlled RCT with 300 participants per group aged 18–60, randomized to Ashwagandha (300 mg/day), melatonin (3 mg/day), or placebo for 12 weeks, with primary outcomes measured by actigraphy (SOL, TST) and secondary outcomes including PSQI and cortisol levels.
Whether long-term use of Ashwagandha or melatonin in real-world settings is associated with sustained improvements in sleep latency and duration over 1–3 years.
A prospective cohort study following 1,500 adults aged 18–60 who self-select to take Ashwagandha (300 mg/day) or melatonin (3 mg/day) daily versus non-users, tracking sleep quality (actigraphy and PSQI) and medication use annually for three years, adjusting for lifestyle and comorbidities.
Whether responders to Ashwagandha or melatonin differ in baseline cortisol, GABA, or melatonin receptor gene variants compared to non-responders.
A case-control study comparing 100 responders (≥15 min reduction in SOL after 8 weeks) to 100 non-responders for each supplement, matched for age and baseline sleep severity, analyzing serum biomarkers and genetic polymorphisms related to HPA axis and circadian regulation.
The prevalence of sleep improvement among adults currently using Ashwagandha or melatonin in the general population and its association with self-reported sleep latency and duration.
A national survey of 5,000 adults aged 18–60 assessing current use of Ashwagandha (300 mg/day) or melatonin (3 mg/day), sleep latency, and total sleep time via validated questionnaires, with adjustment for age, BMI, caffeine, and screen time.